1. Generics Bulletin
  2. >>Products
  3. >>Generics

Mylan Is Latest Entrant On US Generic Suboxone

 
• By Dave Wallace

Mylan has joined Alvogen, Dr Reddy’s and Sandoz in the battle over US generic versions of Indivior’s Suboxone sublingual film. However, it is only marketing two of the four strengths offered by its rivals.

Hat
Mylan Is Throwing Its Hat Into The Ring On Generic Suboxone • Source: Shutterstock

Mylan has launched a generic version of Indivior’s Suboxone (buprenorphine/naloxone) in the US, hot on the heels of launches by Alvogen and Dr Reddy’s as well as Sandoz’ introduction of an authorized generic.

However, the 8mg/2mg and 12mg/3mg strengths launched by Mylan represent only two of the four strengths covered by the other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

US Makes First Reformulated Ranitidine Approval Since Withdrawal, Starting With Rx Tablets

 
• By Malcolm Spicer

In announcement of approving VKT Pharma’s application, FDA included storage and handling instructions common in labeling, suggesting concerns persist about the potential for NDMA to form after products are distributed.

US FDA’s Advertising Enforcement Crackdown Expands To Generic Drugs

 
• By Sue Sutter

A webpage for PharmaTher’s ketamine product lacked risk information and made misleading claims about the approved indication, the FDA said in a rare ad/promo violation letter to an ANDA holder.

Who’s Hired? Alvotech Promotes McClellan To COO

 
• By Dave Wallace

As Alvotech continues to reorganize its senior team with the promotion of chief scientific officer Joseph McClellan to chief operating officer, multiple other firms – including Hikma, Hyloris, CNX and Cingulate – have also announced executive updates.

FDA Publishes New PSGs Including For Generic Zepbound Rivals

 
• By Urtė Fultinavičiūtė

The US FDA delivered its promise to publish product-specific guidances in November, after two late batches earlier this year. Third time might have been a charm, but it remains to be seen if the December batch will be the fourth time guaranteed.

More from Products

Who’s Hired? Alvotech Promotes McClellan To COO

 
• By Dave Wallace

As Alvotech continues to reorganize its senior team with the promotion of chief scientific officer Joseph McClellan to chief operating officer, multiple other firms – including Hikma, Hyloris, CNX and Cingulate – have also announced executive updates.

Prestige Biopharma Signs Another LATAM Deal For Its Trastuzumab Biosimilar

 
• By Urtė Fultinavičiūtė

Prestige Biopharma has picked Biosidus to manufacture and export its Tuznue biosimilar rival to Herceptin across four Latin American countries.

FDA Publishes New PSGs Including For Generic Zepbound Rivals

 
• By Urtė Fultinavičiūtė

The US FDA delivered its promise to publish product-specific guidances in November, after two late batches earlier this year. Third time might have been a charm, but it remains to be seen if the December batch will be the fourth time guaranteed.